Cytof and O-link assessment in the `NCI covid-19 in cancer patients study' (NCCAPS)
Ended Definitive Contract Awarded Last action
- Contract number
- 75N91021C00003
- Awardee
-
Icahn School Of Medicine At Mount Sinai UEI C8H9CNG1VBD9
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,712,342
Award facts
- Opportunity
-
- CyTOF and O-Link Assessment in the NCI COVID-19 in Cancer Patients Study(NCCAPS) Pre-Solicitation · 75N91020R00055 · Posted Oct 14, 2021
- CyTOF and O-Link Assessment in the NCI COVID-19 in Cancer Patients Study (NCCAPS) Award Notice · Posted Dec 28, 2020
- Contract value 100% obligated
- $2,712,342.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541611 Administrative Management and General Management Consulting Services
- Set-aside
- No set-aside
- Competition
- Not Competed · 1 offer Only One Source
- Pricing
- Cost No Fee
- Place of performance
- New York, NY 10029, USA
- Legislative mandates
-
- Davis-Bacon Act FAR subpart 22.4
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $2,712,342 |
About this award
The Department of Health and Human Services' National Institutes of Health National Cancer Institute awarded a $2.7 million cost-plus-fixed-fee contract to Icahn School of Medicine at Mount Sinai. The contract extends an existing agreement to provide expertise and experience assessing cytokine and cellular immune responses in cancer patient samples from the National Cancer Institute's COVID-19 in Cancer Patients Study through O-link and CyTOF assays. The extension will analyze samples from up to 500 additional patients over 12 months to further the scientific goals of understanding immune responses in cancer patients amid the COVID-19 pandemic. As the incumbent contractor, Icahn School of Medicine at Mount Sinai is identified as the only source that can meet the technical requirements to complete the specialized assays within the project timeframe. The award has no set-aside designation and supports the National Cancer Institute's research objectives.
Quick answers
Who was awarded contract 75N91021C00003?
75N91021C00003 was awarded to Icahn School Of Medicine At Mount Sinai by National Cancer Institute (National Institutes of Health) on December 23, 2020.
How much is contract 75N91021C00003 worth?
The government has obligated $2,712,342 on 75N91021C00003.
Was contract 75N91021C00003 competed?
The extent of competition for 75N91021C00003 was not competed. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award